Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.7.6 (
RNA polymerase
)
34,946
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Carbon competition between cell growth and product synthesis is the bottleneck in efficient
N
-acetyl glucosamine (GlcNAc) production in microbial cell factories. In this study, a xylose-induced T7
RNA polymerase
-P
T7
promoter system was introduced in
Escherichia coli
W3110 to control the GlcNAc synthesis. Meanwhile, an arabinose-induced CRISPR interference (CRISPRi) system was applied to adjust cell growth by attenuating the transcription of key growth-related genes. By designing proper sgRNAs, followed by elaborate adjustment of the addition time and concentration of the two inducers, the carbon flux between cell growth and GlcNAc synthesis was precisely redistributed. Comparative metabolomics analysis results confirmed that the repression of
pfkA
and
zwf
significantly attenuated the
TCA
cycle and the synthesis of related amino acids, saving more carbon for the GlcNAc synthesis. Finally, the simultaneous repression of
pfkA
and
zwf
in strain GLA-14 increased the GlcNAc titer by 47.6% compared with that in
E. coli
without the CRISPRi system in a shake flask. GLA-14 could produce 90.9 g/L GlcNAc within 40 h in a 5 L bioreactor, with a high productivity of 2.27 g/L/h. This dynamic strategy for rebalancing cell growth and product synthesis could be applied in the fermentative production of other chemicals derived from precursors synthesized via central carbon metabolism.
...
PMID:CRISPRi-Based Dynamic Control of Carbon Flow for Efficient
N
-Acetyl Glucosamine Production and Its Metabolomic Effects in
Escherichia coli
. 3210 21
<< Previous
1
2
3